Evidence map›Paper›PMID 38897209›Full record

ArticleNeuron2024

Therapeutic potential of human microglia transplantation in a chimeric model of CSF1R-related leukoencephalopathy.

Jean Paul Chadarevian, Jonathan Hasselmann, Alina Lahian, Joia K Capocchi, Adrian Escobar, Tau En Lim, Lauren Le, Christina Tu, Jasmine Nguyen, Sepideh Kiani Shabestari and 9 more

Abstract read
In one paragraph

Article in Neuron, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Microglia replacement by peripheral delivery of CSF1R inhibitor-resistant hematopoietic cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jean Paul ChadarevianDepartment of Neurobiology & Behavior, University of California, Irvine, Irvine, CA, USA; Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA; Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA, USA.
Jonathan HasselmannInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA; Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA, USA.
Alina LahianDepartment of Neurobiology & Behavior, University of California, Irvine, Irvine, CA, USA; Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA; Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA, USA.
Joia K CapocchiInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.
Adrian EscobarSue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA, USA.
Tau En LimInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA; Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA, USA.
Lauren LeInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.
Christina TuInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA; Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA, USA.
Jasmine NguyenInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.
Sepideh Kiani ShabestariDepartment of Neurobiology & Behavior, University of California, Irvine, Irvine, CA, USA; Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA, USA.
William Carlen-JonesInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.
Sunil GandhiDepartment of Neurobiology & Behavior, University of California, Irvine, Irvine, CA, USA.
Guojun BuDivision of Life Science, Hong Kong University of Science and Technology, Hong Kong, China.
David A HumeMater Research Institute, University of Queensland, Brisbane, QLD, Australia.
Clare PridansUniversity of Edinburgh, University of Edinburgh Center for Inflammation Research, Edinburgh, UK.
Zbigniew K WszolekDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Robert C SpitaleDepartment of Pharmaceutical Sciences, University of California, Irvine, Irvine, CA, USA.
Hayk DavtyanInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA; Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA, USA. Electronic address: hdavtyan@uci.edu.
Mathew Blurton-JonesDepartment of Neurobiology & Behavior, University of California, Irvine, Irvine, CA, USA; Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA; Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA, USA. Electronic address: mblurton@uci.edu.

Funding

Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI Bradley F Boeve · 2019 to 2026
$120.9M
Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
Project 4 (Genetic modifiers for APOE-associated Alzheimer's disease pathogenesis)U19AG069701 · NIA · MAYO CLINIC JACKSONVILLE · PI ALISON M GOATE, DAVID M. HOLTZMAN · 2021 to 2026
$42.0M
The Alzheimer's Disease Research Center at the University of California, IrvineP30AG066519 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Mathew Mark Blurton-Jones · 2020 to 2026
$27.9M
Training in the Neurobiology of Aging and Alzheimers DiseaseT32AG000096 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI VIVEK SWARUP, Craig E Stark · 1985 to 2026
$9.6M
Using human iPSC derived microglia and chimeric models to examine the role of PLCG2 in Alzheimers diseaseR01AG061895 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI DAVTYAN, HAYK · 2018 to 2022
$2.9M
Training in Translational ADRD Neuroscience (TITAN)T32AG073088 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Joshua Grill, Elizabeth Head · 2021 to 2026
$2.2M
High-Throughput DNA SequencerS10OD021718 · OD · UNIVERSITY OF CALIFORNIA-IRVINE · PI SANDMEYER, SUZANNE · 2016 to 2016
$600k
PacBio RS Single Molecule, Real-Time (SMRT) DNA SequencerS10OD010794 · OD · UNIVERSITY OF CALIFORNIA-IRVINE · PI SANDMEYER, SUZANNE · 2012 to 2012
$600k
High Throughput DNA SequencerS10RR025496 · NCRR · UNIVERSITY OF CALIFORNIA-IRVINE · PI SANDMEYER, SUZANNE · 2009 to 2009
$500k
Development of a stem cell platform for the treatment of neurodegenerativemicrogliopathiesR43NS124409 · NINDS · SAVANNA BIOTHERAPEUTICS, INC. · PI GANDHI, SUNIL · 2021 to 2021
$399k
NCI NIH HHS P30 CA062203NCRR NIH HHS S10 RR025496NIA NIH HHS P30 AG066519NIA NIH HHS R01 AG061895NIA NIH HHS T32 AG000096NIA NIH HHS T32 AG073088NIA NIH HHS U19 AG063911NIA NIH HHS U19 AG069701NIH HHS S10 OD010794NIH HHS S10 OD021718NINDS NIH HHS R43 NS124409
6 · The paper itself

Abstract

Microglia replacement strategies are increasingly being considered for the treatment of primary microgliopathies like adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). However, available mouse models fail to recapitulate the diverse neuropathologies and reduced microglia numbers observed in patients. In this study, we generated a xenotolerant mouse model lacking the fms-intronic regulatory element (FIRE) enhancer within Csf1r, which develops nearly all the hallmark pathologies associated with ALSP. Remarkably, transplantation of human induced pluripotent stem cell (iPSC)-derived microglial (iMG) progenitors restores a homeostatic microglial signature and prevents the development of axonal spheroids, white matter abnormalities, reactive astrocytosis, and brain calcifications. Furthermore, transplantation of CRISPR-corrected ALSP-patient-derived iMG reverses pre-existing spheroids, astrogliosis, and calcification pathologies. Together with the accompanying study by Munro and colleagues, our results demonstrate the utility of FIRE mice to model ALSP and provide compelling evidence that iMG transplantation could offer a promising new therapeutic strategy for ALSP and perhaps other microglia-associated neurological disorders.

Indexed as

Disease Models, AnimalInduced Pluripotent Stem CellsLeukoencephalopathiesMicrogliaReceptors, Granulocyte-Macrophage Colony-Stimulating FactorAnimalsGliosisHumansMiceReceptor, Macrophage Colony-Stimulating FactorCSF1R protein, humanReceptor, Macrophage Colony-Stimulating FactorReceptors, Granulocyte-Macrophage Colony-Stimulating FactorALSPaxonal spheroidschimeraCRISPR correctionCSF1RFIREhumanizedleukoencephalopathymicroglia

Identifiers

PMID38897209
PMCPMC12357648

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.